{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:55:26Z","timestamp":1790826926451,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1053\/j.gastro.2007.03.053","type":"journal-article","created":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T11:47:41Z","timestamp":1178884061000},"page":"2239-2252","source":"Crossref","is-referenced-by-count":95,"title":["Drug Treatment of the Overweight Patient"],"prefix":"10.1053","volume":"132","author":[{"given":"George A.","family":"Bray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2007.03.053_bib1","series-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report","year":"1998"},{"key":"10.1053\/j.gastro.2007.03.053_bib2","series-title":"The practical guide: identification, evaluation, and treatment for overweight and obesity in adults","year":"2000"},{"key":"10.1053\/j.gastro.2007.03.053_bib3","series-title":"The Surgeon General\u2019s call to action to prevent and decrease overweight and obesity","year":"2001"},{"key":"10.1053\/j.gastro.2007.03.053_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/er.20.6.805","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1053\/j.gastro.2007.03.053_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-142-7-200504050-00011","article-title":"Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians","volume":"142","author":"Snow","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diacare.28.3.736","article-title":"A systematic review of drug therapy to delay or prevent type 2 diabetes","volume":"28","author":"Padwal","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diacare.28.4.942","article-title":"Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies","volume":"28","author":"Vettor","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib9","article-title":"Long-term pharmacotherapy for obesity and overweight","author":"Padwal","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2007.03.053_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/oby.2003.152","article-title":"Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials","volume":"11","author":"Kim","year":"2003","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","article-title":"Anorectics on trial: a half century of federal regulation of prescription appetite suppressants","volume":"143","author":"Colman","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib14","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib15","volume":"Volume 2006","year":"2006"},{"key":"10.1053\/j.gastro.2007.03.053_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2007.03.053_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity","volume":"8","author":"Rossner","year":"2000","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/ENDO:13:2:201","article-title":"Orlistat: selective inhibition of caloric absorption can affect long-term body weight","volume":"13","author":"Hauptman","year":"2000","journal-title":"Endocrine"},{"key":"10.1053\/j.gastro.2007.03.053_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2007.03.053_bib22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","article-title":"Orlistat inhibits dietary cholesterol absorption","volume":"9","author":"Mittendorfer","year":"2001","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib27","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.12.1.18","article-title":"Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents","volume":"12","author":"Maahs","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2007.03.053_bib29","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8210","article-title":"Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement","volume":"8","author":"Avenell","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1053\/j.gastro.2007.03.053_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-277X.2004.00530.x","article-title":"What interventions should we add to weight reducing diets in adults with obesity?","volume":"17","author":"Avenell","year":"2004","journal-title":"J Hum Nutr Diet"},{"key":"10.1053\/j.gastro.2007.03.053_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.164.13.1395","article-title":"Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis","volume":"164","author":"Norris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/00912709922007543","article-title":"Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients","volume":"39","author":"Zhi","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","article-title":"Sibutramine reduces food intake in non-dieting women with obesity","volume":"6","author":"Rolls","year":"1998","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","article-title":"Thermogenic effects of sibutramine in humans","volume":"68","author":"Hansen","year":"1998","journal-title":"Am J Clin Nutr"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.03.053_bib35","first-page":"S30","article-title":"Sibutramine and energy balance","volume":"22","author":"Astrup","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"Am J Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2007.03.053_bib39","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.ejcn.1602172","article-title":"Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study","volume":"59","author":"Mathus-Vliegen","year":"2005","journal-title":"Eur J Clin Nutr"},{"key":"10.1053\/j.gastro.2007.03.053_bib40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib41","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib42","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2007.03.053_bib44","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","article-title":"Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial","volume":"289","author":"Berkowitz","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib45","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","article-title":"Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study","volume":"90","author":"Godoy-Matos","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2007.03.053_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Effects of sibutramine treatment in obese adolescents","volume":"145","author":"Berkowitz","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/oby.2000.53","article-title":"Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial","volume":"8","author":"Wadden","year":"2000","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib48","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1053\/j.gastro.2007.03.053_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008877-200509000-00004","article-title":"Endocannabinoids in the regulation of appetite and body weight","volume":"16","author":"Kirkham","year":"2005","journal-title":"Behav Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ceca.2005.10.005","article-title":"Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell","volume":"39","author":"Juan-Pico","year":"2006","journal-title":"Cell Calcium"},{"key":"10.1053\/j.gastro.2007.03.053_bib52","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2007.03.053_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2007.03.053_bib54","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"key":"10.1053\/j.gastro.2007.03.053_bib56","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1381\/0960892041590818","article-title":"The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery","volume":"14","author":"Patriti","year":"2004","journal-title":"Obes Surg"},{"key":"10.1053\/j.gastro.2007.03.053_bib57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1568007043336950","article-title":"Gut hormones as peripheral anti obesity targets","volume":"3","author":"Small","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archsurg.137.10.1109","article-title":"Effects of obesity surgery on non-insulin-dependent diabetes mellitus","volume":"137","author":"Greenway","year":"2002","journal-title":"Arch Surg"},{"key":"10.1053\/j.gastro.2007.03.053_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2004-814222","article-title":"Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion","volume":"36","author":"Lugari","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","article-title":"Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1","volume":"29","author":"Riddle","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib61","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/en.141.6.1936","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1053\/j.gastro.2007.03.053_bib62","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"10.1053\/j.gastro.2007.03.053_bib63","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/meta.2000.6251","article-title":"Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats","volume":"49","author":"Rodriquez de Fonseca","year":"2000","journal-title":"Metabolism"},{"key":"10.1053\/j.gastro.2007.03.053_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib65","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.gastro.2007.03.053_bib66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1053\/j.gastro.2007.03.053_bib67","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib68","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib69","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2007.03.053_bib70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2007.03.053_bib72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0014-2999(02)01427-9","article-title":"Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status","volume":"440","author":"Parker","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib73","first-page":"1198","article-title":"Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs","volume":"4","author":"Levens","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1053\/j.gastro.2007.03.053_bib74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0960-894X(01)00761-2","article-title":"Dihydropyridine neuropeptide Y Y(1) receptor antagonists","volume":"12","author":"Poindexter","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1053\/j.gastro.2007.03.053_bib75","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/mol.59.3.501","article-title":"A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814","volume":"59","author":"Kanatani","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib76","first-page":"403","article-title":"Neuropeptide Y in obese women during treatment with adrenergic modulation drugs","volume":"7","author":"Zahorska-Markiewicz","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1053\/j.gastro.2007.03.053_bib77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2007.03.053_bib78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1139\/y04-025","article-title":"Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity","volume":"82","author":"Gibson","year":"2004","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib79","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/jm058240i","article-title":"5-Hydroxytryptamine 2C (5-HT2C) receptor\/agonists as potential antiobesity agents","volume":"49","author":"Nilsson","year":"2006","journal-title":"J Med Chem"},{"key":"10.1053\/j.gastro.2007.03.053_bib80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ajcn\/56.5.863","article-title":"Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan","volume":"56","author":"Cangiano","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2007.03.053_bib81","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/sj.ijo.0800642","article-title":"Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients","volume":"22","author":"Cangiano","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00427624","article-title":"Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects","volume":"66","author":"Rogers","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1053\/j.gastro.2007.03.053_bib83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0031-9384(95)02098-5","article-title":"Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory","volume":"59","author":"Foltin","year":"1996","journal-title":"Physiol Behav"},{"key":"10.1053\/j.gastro.2007.03.053_bib84","first-page":"299","article-title":"The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks","volume":"19","author":"Drent","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.470100504","article-title":"Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women","volume":"10","author":"Cowen","year":"1995","journal-title":"Hum Psychopharmacol"},{"key":"10.1053\/j.gastro.2007.03.053_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002130050178","article-title":"Sumatriptan decreases food intake and increases plasma growth hormone in healthy women","volume":"129","author":"Boeles","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1053\/j.gastro.2007.03.053_bib87","unstructured":"Website. http:\/\/www.clinicaltrials.gov\/t\/show\/NCT00104507?order=1."},{"key":"10.1053\/j.gastro.2007.03.053_bib88","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3-36","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1053\/j.gastro.2007.03.053_bib89","first-page":"A28","article-title":"Intranasal peptide YY 3-36: phase 1 dose ranging and dose sequencing studies","volume":"12","author":"Brandt","year":"2004","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2007.03.053_bib90","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1053\/j.gastro.2007.03.053_bib91","first-page":"S135","article-title":"Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962","volume":"26","author":"Dunk","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2007.03.053_bib92","first-page":"A395","article-title":"A randomised, placebo-controlled, trial of cetilistat (ATL-962), a novel lipase inhibitor and orlistat (Xenical\u00a9) for the management of obese type 2 diabetic patients","volume":"55","author":"Kopelman","year":"2006","journal-title":"Diabetes Metab"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507005744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508507005744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T21:23:48Z","timestamp":1556400228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508507005744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0016508507005744"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2007.03.053","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}